Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) shares hit a new 52-week low on Tuesday . The company traded as low as GBX 175 ($2.27) and last traded at GBX 180.30 ($2.34), with a volume of 39831 shares changing hands. The stock had previously closed at GBX 184.75 ($2.40).
Hemogenyx Pharmaceuticals Stock Performance
The stock has a market capitalization of £6.43 million, a PE ratio of -922.33 and a beta of 3.14. The stock has a 50 day moving average of GBX 334.59 and a two-hundred day moving average of GBX 161.20. The company has a debt-to-equity ratio of 90.87, a current ratio of 4.38 and a quick ratio of 6.72.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Featured Articles
- Five stocks we like better than Hemogenyx Pharmaceuticals
- 3 Tickers Leading a Meme Stock Revival
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Must-Own Stocks to Build Wealth This Decade
- Top Biotech Stocks: Exploring Innovation Opportunities
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
